Global Next Generation Cancer Diagnostic Devices Market Growth 2023-2029

Global Next Generation Cancer Diagnostic Devices Market Growth 2023-2029

LPI (LP Information)' newest research report, the “Next Generation Cancer Diagnostic Devices Industry Forecast” looks at past sales and reviews total world Next Generation Cancer Diagnostic Devices sales in 2022, providing a comprehensive analysis by region and market sector of projected Next Generation Cancer Diagnostic Devices sales for 2023 through 2029. With Next Generation Cancer Diagnostic Devices sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Next Generation Cancer Diagnostic Devices industry.

This Insight Report provides a comprehensive analysis of the global Next Generation Cancer Diagnostic Devices landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Next Generation Cancer Diagnostic Devices portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Next Generation Cancer Diagnostic Devices market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Next Generation Cancer Diagnostic Devices and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Next Generation Cancer Diagnostic Devices.

The global Next Generation Cancer Diagnostic Devices market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Next Generation Cancer Diagnostic Devices is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Next Generation Cancer Diagnostic Devices is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Next Generation Cancer Diagnostic Devices is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Next Generation Cancer Diagnostic Devices players cover Roche Holding Ltd.（Switzerland), Abbott Laboratories(US), Siemens Healthcare(Germany), Agilent Technologies Inc(Germany), Illumina Inc.(US), Becton Dickinson and Co.(US), QIAGEN N.V.(Germany), Affymetrix Inc.(US) and Johnson & Johnson(US), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Next Generation Cancer Diagnostic Devices market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Next Generation Sequencing
qPCR & Multiplexing
Lab-on- a- chip (LOAC)
Protein Microarrays
DNA Microarrays
Reverse Transcriptase-PCR (RT-PCR)

Segmentation by application
Biomarker Development
CTC Analysis
Proteomic Analysis
Epigenetic Analysis
Genetic Analysis

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche Holding Ltd.（Switzerland)
Abbott Laboratories(US)
Siemens Healthcare(Germany)
Agilent Technologies Inc(Germany)
Illumina Inc.(US)
Becton Dickinson and Co.(US)
QIAGEN N.V.(Germany)
Affymetrix Inc.(US)
Johnson & Johnson(US)
Thermo Fisher Scientific Inc.(US)
GE Healthcare(England)
Life Technologies Corp.(US)
Luminex Corp.(US)
Cepheid Inc.(US)
Allegro Diagnostics Corp.(Brazil)

Key Questions Addressed in this Report

What is the 10-year outlook for the global Next Generation Cancer Diagnostic Devices market?

What factors are driving Next Generation Cancer Diagnostic Devices market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Next Generation Cancer Diagnostic Devices market opportunities vary by end market size?

How does Next Generation Cancer Diagnostic Devices break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.